<DOC>
	<DOCNO>NCT03061097</DOCNO>
	<brief_summary>This study , Randomized control trial Autologous microbiome reconstitution prevent Colonization antibiotic rEsistant bacteria ( RACE ) , seek investigate safety , feasibility role autologous fecal microbiota transplantation ( FMT ) prevention antibiotic resistant bacteria ( ARB ) microbiome restoration .</brief_summary>
	<brief_title>Autologous Fecal Microbiota Transplantation Prevent Antibiotic Resistant Bacteria Colonization</brief_title>
	<detailed_description />
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<criteria>Inclusion criterion study enrollment 1 . Longterm care resident Boston 2 . Adults ( 18 year old ) Inclusion criterion randomization 1 ) Infection require antimicrobial treatment discretion treat physician Exclusion criterion study enrollment 1 . Oral intravenous antibiotic exposure within previous 6 week stool collection date Topical antibiotic permit 2 . Pregnant . Participants childbearing age undergo urine pregnancy test . 3 . Participant substitute decision maker unable provide inform consent 4 . Active gastrointestinal infection stool collection 5 . Fever time stool collection 6 . Patients allergy follow ingredient Generally Recognized Safe : glycerol sodium chloride 7 . Life expectancy &lt; 6 month 8 . Unable adhere protocol requirement 9 . Any condition physician investigator deem unsafe , include condition medication investigator determines put participant great risk FMT 10 . Stool culture positive common enteric pathogen ( Salmonella spp. , Shigella spp. , Campylobacter spp . ) 11 . Recent travel ( last six month ) high risk region base International SOS Medical Risk Rating system 12 . Recent exposure ( last six month ) unsafe drinking water Exclusion criterion randomization History gastrointestinal ( GI ) symptom ( limited ) vomit diarrhea within 30 day collection enrollment stool AND enrollment stool test positive one Vibrio spp. , Norovirus , Rotavirus , Adenovirus , Shiga toxin Colonized CRE ( assess PCR assay stool collect biobanking phase ) Colonized VRE ( assess PCR assay stool collect biobanking phase ) Colonized ESBL ( assess PCR assay stool collect biobanking phase ) Colonized CDI ( assess EIA assay stool collect biobanking phase ) Treatment antibiotic active MRSA ( i.e . vancomycin linezolid ) prior randomization FMT intervention placebo . Exclusion criterion capsule delivery ; contraindicate , enema delivery offer Dysphagia inability swallow 'safety test ' capsule History severe gastroparesis History severe intestinal obstruction Any condition physician investigator deem unsafe</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Autologous Fecal Microbiota Transplantation</keyword>
</DOC>